Retrieve available abstracts of 29 articles: HTML format
Single Articles
May 2025
CASCONE T, Bonanno L, Guisier F, Insa A, et al Perioperative durvalumab plus chemotherapy plus new agents for resectable
non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
Nat Med. 2025 May 31. doi: 10.1038/s41591-025-03746. PubMedAbstract available
SKOULIDIS F, Li BT, de Langen AJ, Hong DS, et al Molecular determinants of sotorasib clinical efficacy in KRAS(G12C)-mutated
non-small-cell lung cancer.
Nat Med. 2025 May 28. doi: 10.1038/s41591-025-03732. PubMedAbstract available
ZHENG MM, Zhou Q, Chen HJ, Jiang BY, et al Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and
matched treatment of central nervous system metastases.
Nat Med. 2025;31:1547-1556. PubMedAbstract available
April 2025
ZHAO S, Cheng Y, Wang Q, Li X, et al Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without
EGFR mutations: phase 1/2 and phase 2 trials.
Nat Med. 2025 Apr 10. doi: 10.1038/s41591-025-03638. PubMedAbstract available
March 2025
HERBST RS, John T, Grohe C, Goldman JW, et al Molecular residual disease analysis of adjuvant osimertinib in resected
EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
Nat Med. 2025 Mar 17. doi: 10.1038/s41591-025-03577. PubMedAbstract available
February 2025
TAGORE S, Caprio L, Amin AD, Bestak K, et al Single-cell and spatial genomic landscape of non-small cell lung cancer brain
metastases.
Nat Med. 2025 Feb 27. doi: 10.1038/s41591-025-03530. PubMedAbstract available
January 2025
SHI Y, Fang J, Xing L, Yao Y, et al Glecirasib in KRAS(G12C)-mutated nonsmall-cell lung cancer: a phase 2b trial.
Nat Med. 2025 Jan 6. doi: 10.1038/s41591-024-03401. PubMedAbstract available
BLACK JRM, Bartha G, Abbott CW, Boyle SM, et al Ultrasensitive ctDNA detection for preoperative disease stratification in
early-stage lung adenocarcinoma.
Nat Med. 2025;31:70-76. PubMedAbstract available
ZUCCATO JA, Mamatjan Y, Nassiri F, Ajisebutu A, et al Prediction of brain metastasis development with DNA methylation signatures.
Nat Med. 2025;31:116-125. PubMedAbstract available
November 2024
ALBAN TJ, Riaz N, Parthasarathy P, Makarov V, et al Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during
immunotherapy with nivolumab.
Nat Med. 2024;30:3209-3222. PubMedAbstract available
WANG C, Shao J, He Y, Wu J, et al Data-driven risk stratification and precision management of pulmonary nodules
detected on chest computed tomography.
Nat Med. 2024;30:3184-3195. PubMedAbstract available
September 2024
LI N, Wang SY Navigating treatment combinations in small-cell lung cancer.
Nat Med. 2024 Sep 18. doi: 10.1038/s41591-024-03255. PubMed
JEE J, Brannon AR, Singh R, Derkach A, et al DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism.
Nat Med. 2024;30:2499-2507. PubMedAbstract available
August 2024
ROBICHAUX JP, Elamin YY, Tan Z, Carter BW, et al Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon
20-selective kinase inhibitor in non-small cell lung cancer.
Nat Med. 2024 Aug 20. doi: 10.1038/s41591-024-03178. PubMed
July 2024
CHENG Y, Chen J, Zhang W, Xie C, et al Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung
cancer: a randomized phase 3 trial.
Nat Med. 2024 Jul 11. doi: 10.1038/s41591-024-03132. PubMedAbstract available
June 2024
PETERS S, Gadgeel SM, Mok T, Nadal E, et al Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3
BFAST trial.
Nat Med. 2024 Jun 19. doi: 10.1038/s41591-024-03008. PubMedAbstract available
WIDMAN AJ, Shah M, Frydendahl A, Halmos D, et al Ultrasensitive plasma-based monitoring of tumor burden using
machine-learning-guided signal enrichment.
Nat Med. 2024;30:1655-1666. PubMedAbstract available
May 2024
SHIELDS MD, Lovly CM Refining neoadjuvant immunotherapy for resectable lung cancer.
Nat Med. 2024 May 13. doi: 10.1038/s41591-024-03001. PubMed
ZENG Y, Hu CH, Li YZ, Zhou JS, et al Association between pretreatment emotional distress and immune checkpoint
inhibitor response in non-small-cell lung cancer.
Nat Med. 2024 May 13. doi: 10.1038/s41591-024-02929. PubMedAbstract available
April 2024
SCHULER M, Cuppens K, Plones T, Wiesweg M, et al Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell
lung cancer: a randomized phase 2 trial.
Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02965. PubMedAbstract available
TAMMEMAGI MC, Darling GE, Schmidt H, Walker MJ, et al Risk-based lung cancer screening performance in a universal healthcare setting.
Nat Med. 2024;30:1054-1064. PubMedAbstract available
VAIDYA A, Chen RJ, Williamson DFK, Song AH, et al Demographic bias in misdiagnosis by computational pathology models.
Nat Med. 2024;30:1174-1190. PubMedAbstract available
SINGHAL A, Li BT, O'Reilly EM Targeting KRAS in cancer.
Nat Med. 2024;30:969-983. PubMedAbstract available
GHILARDI G, Fraietta JA, Gerson JN, Van Deerlin VM, et al T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell
therapy.
Nat Med. 2024;30:984-989. PubMedAbstract available
February 2024
BESSE B, Pons-Tostivint E, Park K, Hartl S, et al Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell
lung cancer: a phase 2 umbrella trial.
Nat Med. 2024 Feb 13. doi: 10.1038/s41591-024-02808. PubMedAbstract available
October 2023
DEUTSCH JS, Cimino-Mathews A, Thompson E, Provencio M, et al Association between pathologic response and survival after neoadjuvant therapy in
lung cancer.
Nat Med. 2023 Oct 30. doi: 10.1038/s41591-023-02660. PubMedAbstract available
CHAFT JE, Oezkan F, Kris MG, Bunn PA, et al Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung
cancer: an open-label, single-arm phase II trial.
Nat Med. 2023 Oct 10. doi: 10.1038/s41591-023-02627. PubMed
ANAGNOSTOU V, Ho C, Nicholas G, Juergens RA, et al ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2
adaptive trial results.
Nat Med. 2023 Oct 9. doi: 10.1038/s41591-023-02598. PubMedAbstract available
September 2023
CHO BC, Kim DW, Spira AI, Gomez JE, et al Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced
non-small cell lung cancer: a phase 1 trial.
Nat Med. 2023 Sep 14. doi: 10.1038/s41591-023-02554. PubMedAbstract available